These authors contributed equally to this work.
Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers
Article first published online: 4 JUL 2013
Copyright © 2013 EMBO Molecular Medicine
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 8, pages 1180–1195, August 2013
How to Cite
Emadali, A., Rousseaux, S., Bruder-Costa, J., Rome, C., Duley, S., Hamaidia, S., Betton, P., Debernardi, A., Leroux, D., Bernay, B., Kieffer-Jaquinod, S., Combes, F., Ferri, E., McKenna, C. E., Petosa, C., Bruley, C., Garin, J., Ferro, M., Gressin, R., Callanan, M. B. and Khochbin, S. (2013), Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med, 5: 1180–1195. doi: 10.1002/emmm.201202034
See accompanying article 10.1002/emmm.201303018
- Issue published online: 5 AUG 2013
- Article first published online: 4 JUL 2013
- Manuscript Accepted: 21 MAY 2013
- Manuscript Revised: 17 MAY 2013
- Manuscript Received: 8 NOV 2012
- Université Joseph Fourier and CHU-Grenoble
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|emmm201202034.reviewer_comments.pdf||PDF document||408K||Review Process File|
Figure S1 Proteomic analysis of a DLBCL nuclear acid soluble (NAS) fraction and identification of nuclear factors which show evidence of abnormal de-repression in lymphoma.
Figure S2. Association of H2AFY and CYCLON levels with clinical outcome in DLBCL.
Figure S3. Establishment of CYCLON knock-down lymphoma cell lines.
Figure S4. Differential expression of genes in CYCLON knock-down Raji lymphoma B cells.
Figure S5. Evaluation of drug sensitivity in CYCLON knock-down B lymphoma cells.
Figure S6. Characterization of JQ1 final compound.
Figure S7. Cell death assays upon JQ1 and JQ1/etoposide treatment.
Table S1. Protein list from LC-MS/MS analysis of B593 NAS fraction.
Table S2. Genes significantly modulated between Raji shCtrl and Raji shCYCLON cell lines.
Table S3. GSEA ‘Aggressive multiple myeloma’ signature.
Table S4. GSEA ‘CD40 dependent B cell’ signature.
Table S5. Oligonucleotides used for this study.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.